The stock of Ideaya Biosciences Inc (IDYA) has gone up by 4.86% for the week, with a 26.79% rise in the past month and a 16.69% rise in the past quarter. The volatility ratio for the week is 3.29%, and the volatility levels for the past 30 days are 3.04% for IDYA. The simple moving average for the last 20 days is 9.64% for IDYA’s stock, with a simple moving average of -10.36% for the last 200 days.
Is It Worth Investing in Ideaya Biosciences Inc (NASDAQ: IDYA) Right Now?
IDYA has 36-month beta value of 0.03. Analysts have mixed views on the stock, with 10 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IDYA is 78.78M, and currently, short sellers hold a 13.32% ratio of that float. The average trading volume of IDYA on June 12, 2025 was 1.42M shares.
IDYA) stock’s latest price update
The stock price of Ideaya Biosciences Inc (NASDAQ: IDYA) has jumped by 0.94 compared to previous close of 21.92. Despite this, the company has seen a gain of 4.86% in its stock price over the last five trading days. prnewswire.com reported 2025-06-02 that SOUTH SAN FRANCISCO, Calif., June 2, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
Analysts’ Opinion of IDYA
Many brokerage firms have already submitted their reports for IDYA stocks, with Stephens repeating the rating for IDYA by listing it as a “Overweight.” The predicted price for IDYA in the upcoming period, according to Stephens is $51 based on the research report published on November 18, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see IDYA reach a price target of $27. The rating they have provided for IDYA stocks is “Market Perform” according to the report published on November 05th, 2024.
UBS gave a rating of “Buy” to IDYA, setting the target price at $50 in the report published on October 24th of the previous year.
IDYA Trading at 18.35% from the 50-Day Moving Average
After a stumble in the market that brought IDYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.19% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IDYA starting from Jason Throne, who proposed sale 75,000 shares at the price of $40.22 back on Aug 26 ’24. After this action, Jason Throne now owns shares of Ideaya Biosciences Inc, valued at $3,016,500 using the latest closing price.
Stock Fundamentals for IDYA
Current profitability levels for the company are sitting at:
- -51.48 for the present operating margin
- 0.75 for the gross margin
The net margin for Ideaya Biosciences Inc stands at -43.76. The total capital return value is set at -0.34. Equity return is now at value -31.34, with -29.78 for asset returns.
Based on Ideaya Biosciences Inc (IDYA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -10.17.
Currently, EBITDA for the company is -326.98 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 259.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.92.
Conclusion
To put it simply, Ideaya Biosciences Inc (IDYA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
